Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Ovarian Neoplasms 25Peritoneal Neoplasms 17Fallopian Tube Neoplasms 11Colorectal Neoplasms 8Stomach Neoplasms 6Carcinoma, Ovarian Epithelial 6Neoplasms 3Hyperthermia 3Gastrointestinal Neoplasms 3Colonic Neoplasms 3Appendiceal Neoplasms 3Adrenocortical Carcinoma 3Sarcoma 2Rhabdomyosarcoma 2Recurrence 2Mesothelioma, Malignant 2Mesothelioma 2Glioma 2Glioblastoma 2Desmoplastic Small Round Cell Tumor 2Carcinoma 2Brain Neoplasms 2Adenoma, Islet Cell 2Wilms Tumor 1Retroperitoneal Neoplasms 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Postoperative Complications 1Pleural Effusion, Malignant 1Peritoneal Cavity Cancer 1

Interventions

Temozolomide 163Radiosurgery 128Radiotherapy 106Bevacizumab 97Magnetic Resonance Spectroscopy 74Carboplatin 48Surgical Procedures, Operative 35Etoposide 34pembrolizumab 33Radiation 33Nivolumab 33Irinotecan 33Cyclophosphamide 33Erlotinib Hydrochloride 31Carmustine 28Trastuzumab 25Lomustine 25Cisplatin 25Ipilimumab 24Filgrastim 23Mental Status and Dementia Tests 21Magnetic Resonance Imaging 21Aminolevulinic Acid 21Vincristine 20Surveys and Questionnaires 19Capecitabine 19Topotecan 18Specimen Handling 18Pemetrexed 18Radiotherapy, Intensity-Modulated 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Brain Neoplasms × Cytoreduction Surgical Procedures × Clear all
NCT01257594 2023-05-25

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Columbia University

Phase 1 Completed
22 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02238496 2023-05-25

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Columbia University

Phase 1 Completed
10 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡